Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Globe Newswire•04/11/2026•09:02 ET
3
Key Highlights
- ➤Eight ziftomenib abstracts accepted for ASH 2026, including four oral presentations
- ➤First ziftomenib data with quizartinib and gilteritinib will target NPM1/FLT3-mutated AML
- ➤Longer-term venetoclax/azacitidine data support ongoing Phase 3 KOMET-017 study
- ➤Exploratory analysis evaluates ziftomenib activity beyond NPM1 and KMT2A AML subtypes
- ➤Kura and Kyowa Kirin will host investor webcast December 15, 2026
Expert Statements
Mollie Leoni, Chief Medical Officer of Kura Oncology
“Our strategy is to establish ziftomenib as a preferred menin inhibitor for combination treatment, supported by clinical evidence across complementary therapeutic approaches.”
Mollie Leoni, Chief Medical Officer of Kura Oncology
“Our first clinical results with quizartinib and gilteritinib extend this strategy into FLT3 inhibitor combinations.”
Mollie Leoni, Chief Medical Officer of Kura Oncology
“Together with longer-term venetoclax and azacitidine results and studies of additional combinations, these presentations will help define ziftomenib’s potential as a backbone therapy from initial diagnosis through relapsed or refractory disease.”
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –
– Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study –
Get started
Create a free account to read the full story.